Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
31 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
87
87 articles ont été cités au moins 87fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
41 552
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
1185
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
401
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Cochin
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Phosphate Mining Residues as Novel Substrate for Advanced Vertical Flow Constructed Wetlands: A Circular Economy Approach
2026ArticleAgronomy
Increasing propellant gas emissions from pressurized metered-dose inhalers in obstructive lung diseases in France over 11 years
2026ArticleRespiratory Research
Clinical impact and healthcare resource utilisation in patients with unexplained or refractory chronic cough: a French national population study
2026ArticleERJ Open Research
Expositions hormonales au cours de la vie, asthme actuel et fonction respiratoire des femmes : données de la cohorte CONSTANCES
2026CongrèsCongrès de Pneumologie de Langue Française (CPLF)
Exposition aux moisissures au domicile, cytokines des voies T2/non-T2/Th17 et asthme dans la cohorte en population-générale CONSTANCES
2026CongrèsCongrès de Pneumologie de Langue Française (CPLF)
Caractérisation des phénotypes inflammatoires sanguins dans la BronchoPneumopathie Chronique Obstructive et la pré-BPCO en population générale : la cohorte CONSTANCES
2026CongrèsCongrès de Pneumologie de Langue Française (CPLF)
Longitudinal Motor Function Changes in Adults With Late-Onset Pompe Disease
2026ArticleNeurology
Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study
2026ArticleScientific Reports
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2025
Allergy · 2024
Abstract Background Biologic asthma therapies reduce exacerbations and long‐term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real‐world population of adults with severe asthma. Methods Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow‐up were grouped into those who did, or did not, initiate biologics (anti‐IgE, anti‐IL5/IL5R, anti‐IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV 1 ) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super‐response criteria were: FEV 1 increase by ≥500 mL, new well‐controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. Results 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non‐initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV 1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super‐responses. Responses/super‐responses were more frequent in biologic initiators than in non‐initiators; nevertheless, ~40–50% of initiators did not meet response criteria. Conclusions Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non‐initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super‐responses in all outcome domains, 40–50% did not meet the response criteria.
The Lancet. Respiratory medicine · 2025
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
American journal of respiratory and critical care medicine · 2026 · Journal Article
Wedzicha JA, Agustí À, Brightling CE, Calverley P, et al.
Neurology · 2026 · Journal Article
Maulet T, Bonnyaud C, Dubois F, Roche N, et al.
International journal of chronic obstructive pulmonary disease · 2026 · Journal Article
Singh D, Roche N, Wu L, Sadafi H, et al.
Presse medicale (Paris, France : 1983) · 2026 · Editorial
Roche N
Respiratory medicine and research · 2025 · Editorial
Ribeiro-Baptista B, Girodet PO, Le Rouzic O, Zysman M, et al.
Respiratory medicine and research · 2025 · Journal Article
Lavault S, Roche N, Morélot-Panzini C, Straus C, et al.
Respiratory medicine and research · 2025 · Journal Article
Roche N, Zysman M, Aboyans V, Deslee G, et al.
Environmental research · 2025 · Journal Article
Tsiavia T, Fréalle E, Bex V, Dumas O, et al.
American journal of respiratory and critical care medicine · 2025 · Journal Article
Krishnan JA, Cao B, Chotirmall SH, Ely EW, et al.
International journal of chronic obstructive pulmonary disease · 2025 · Journal Article
Singh D, Roche N, Wu L, Sadafi H, et al.
American journal of industrial medicine · 2025 · Journal Article
Ibrahim B, Le Moual N, Sit G, Goldberg M, et al.
The New England journal of medicine · 2025 · Journal Article
Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, et al.
Respiratory medicine and research · 2025 · Journal Article
Haudebourg L, Faure M, Dres M, Roche N, et al.
American journal of respiratory and critical care medicine · 2025 · Editorial
Regard L, Perez T, Roche N
The Lancet. Respiratory medicine · 2025 · Letter
Roche N, Johannson KA
The Lancet. Respiratory medicine · 2025 · Journal Article
van Boven JFM, Costello RW, Roes KCB, Brusselle GG, et al.
Journal of aerosol medicine and pulmonary drug delivery · 2025 · Journal Article
Roche N, Usmani O, Franzini L, Labadini L, et al.
The European respiratory journal · 2024 · Letter
van Boven JFM, Yorgancioglu A, Roche N, Usmani OS
Chest · 2024 · Journal Article
Lough G, Bosnic-Anticevich S, Roche N, Usmani OS
Respiratory medicine and research · 2024 · Journal Article
Raherison C, Aguilaniu B, Zysman M, Burgel PR, et al.
ERJ open research · 2025 · Journal Article
Roche N, Molinari N, Watier L, Schmidt A, et al.
Pragmatic and observational research · 2025 · Journal Article
Del Giacco S, Canonica GW, Agache I, Price D, et al.
Journal of aerosol medicine and pulmonary drug delivery · 2025 · Letter
Usmani OS, Al-Ahmad M, Allan K, Anzueto A, et al.
Lancet (London, England) · 2026 · Journal Article
Papi A, Greening NJ, Bhatt SP, Roche N, et al.
BMC pulmonary medicine · 2026 · Journal Article
Regard L, Paillasseur JL, Burgel PR, Roche N
NPJ primary care respiratory medicine · 2026 · Journal Article
Usmani OS, Roche N, van Boven JFM, Scullion J, et al.
International journal of chronic obstructive pulmonary disease · 2025 · Journal Article
Di Marco F, Shahaj O, Valipour A, Legrand B, et al.
Advances in therapy · 2026 · Journal Article
Garcia G, Maneechotesuwan K, Krishnan P, Verma M, et al.
International journal of chronic obstructive pulmonary disease · 2025 · Journal Article
Molinari N, Roche N, Vataire AL, Perrier S, et al.
Allergy · 2024 · Journal Article
Denton E, Hew M, Peters MJ, Upham JW, et al.
Lancet (London, England) · 2026 · Journal Article
Papi A, Greening NJ, Bhatt SP, Roche N, et al.
Journal of environmental management · 2025 · Journal Article
Jari Y, Najid N, Necibi MC, Gourich B, et al.
Rising total costs and mortality rates associated with admissions due to COPD exacerbations
Abstract Background To examine trends in mortality, costs and in-hospital management and outcomes of severe COPD exacerbations admitted in France. Methods Patients hospitalized from 2007 to 2012 with COPD exacerbation as
Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
Abstract Background Dry powder inhalers (DPIs) are often used in asthma and chronic obstructive pulmonary disease (COPD) therapies. Using the discrete choice experiment (DCE) methodology, this study conducted in France w
Are there specific clinical characteristics associated with physician’s treatment choices in COPD?
Abstract Background The number of pharmacological agents and guidelines available for COPD has increased markedly but guidelines remain poorly followed. Understanding underlying clinical reasoning is challenging and coul
Is atopy a risk indicator of chronic obstructive pulmonary disease in dairy farmers?
Abstract Allergic mechanisms related to environmental and occupational exposure have been suggested to contribute to the development of chronic obstructive pulmonary disease (COPD). Objectives To investigate the relation
Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Groupâ European Academy of Allergy and Clinical Immunology Task Force
Abstract Introduction A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-l
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Allergy · 2024 · Journal Article
Denton E, Hew M, Peters MJ, Upham JW, et al.